



TECHNICAL DATA SHEET

Orgasol[®] 3501 EXD NAT 1



MAIN APPLICATIONS

Transfer paper for inkjet, Metal powder compounds, Powder Injection Molding, Metal Injection Molding.

ORGASOL[®] 3501 EXD NAT 1 is a **spheroïdal powder** of copolyamide 6/12, with **10 µm** as average diameter and a narrow particle size distribution. An extremely high level of quality is achieved thanks to our rigorous control of particle size distribution, providing **excellent consistency in performance**.

ORGASOL[®] 3501 EXD NAT 1 consists of **unique highly porous particles**. The Lactame 6/Lactame 12 ratio is adjusted to reach **Melting Temperature around 142°C**.

The **hydrophilicity of Lactame 6** facilitates the dispersion of ORGASOL[®] 3501 EXD NAT 1 in water based formulations.

ORGASOL[®] 3501 EXD NAT 1 is a **leading product in the transfer paper technology for inkjet printing**. It exhibits a unique combination of performances: a perfect printability quality, a very high ink acceptance and an efficient transfer of the image from the paper to the textile substrate, guarantying a high wash resistance.

For Powder Injection Technology, ORGASOL[®] 3501 EXD NAT 1 is a key polymer offering a wide range of properties to improve the end products performance. It plays the role of a **solid lubricant**. Combined with the other components of the molding feedstocks, it imparts **high strength into the moulded green parts** in order to avoid damage of the parts on ejection of the mould.

CHARACTERISTICS

METHOD

Appearance:	White spheroïdal powder	Visual
Average diameter:	10 microns	ISO 13319
Particle size distribution:		
Fine particles < 5 microns	10 max. %	ISO 13319
Coarse particles > 20 microns	5 max. %	ISO 13319
Average Specific Surface Area:	20 m ² /g	ISO 9277
Apparent density unpacked:	0.265 g/cm ³	ISO 1068
Melting point:	142 °C	ISO 11357-3

PACKAGING

10 Kg multilayers bags

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html>) Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Headquarters: Arkema France

420 rue d'Estienne d'Orves
92705 Colombes Cedex – France
Tel.: 33 (0)1 49 00 80 80
Fax: 33 (0)1 49 00 83 96
arkema.com